Organon Acquired by Sun Pharmaceutical Industries | Healthcare M&A Deal

Sun Pharmaceutical Industries has acquired Organon, a pharmacy business in the United States, for $11.75 billion. Sun Pharmaceutical Industries acquisitions target Organon & Co., a global healthcare company with women’s health, biosimilars, and general medicines sold across multiple markets. Organon acquisition strengthens Sun Pharmaceutical Industries’ platform acquisition strategy by expanding manufacturing footprint and product portfolio, supporting growth in women’s health and biosimilars. The healthcare M&A is an all-cash strategic acquisition for all outstanding shares at $14 per share, with boards approving and an expected close in early 2027 subject to regulatory clearances and shareholder approval.